Literature DB >> 3495566

Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.

T Kalland, H Belfrage, P Bhiladvala, G Hedlund.   

Abstract

Murine as well as human lymphokine-activated killer (LAK) cells have been reported to have several characteristics of T lymphocytes and to be clearly distinct from natural killer (NK) cells. The present study of murine LAK cells showed that cytotoxic cells generated in the presence of interleukin 2 IL 2 were heterogeneous with respect to cell surface markers of progenitor as well as effector cells. Negative selection of cells with antibodies and complement or positive selection by fluorescence-activated cell sorting unequivocally showed that LAK effector cells consisted of at least two clearly distinct populations, the relative contribution of which was dependent on donor organ and target cells studied. Approximately 40% of the cytotoxic activity of spleen-derived effector cells active against the NK-resistant targets EL-4 or MCA-5 was eliminated by treatment with antibodies to the NK-markers asialo-GM1 and NK 1 (NK-LAK). Approximately 60% of cytotoxic activity was associated with cells expressing the T cell marker Lyt-2, lacked NK 1, and was lacking or expressed only small amounts asialo-GM1 (T-LAK). The NK-LAK cells were of greater importance for the cytotoxic activity against the standard NK target YAC-1, although T-LAK cells also excerted significant cytotoxicity against this cell line. Limiting dilution analysis estimated that the minimal frequency of precursors developing into cells with cytotoxic activity against EL-4 was 1/6700 in spleen and 1/4200 in peripheral blood. The frequency of cells developing into cytotoxic effectors against YAC-1 cells was 1/3700 and 1/1450 in spleen and peripheral blood, respectively. Depletion of progenitor cells from spleen or peripheral blood expressing NK 1 or Lyt-2 by treating the cells with antibodies to these structures and complement indicated that NK-1-expressing cells were the dominating progenitor of the LAK cells irrespective of target cells used. Culture of murine lymphoid cells from spleen or peripheral blood with high concentrations of IL 2 results in the emergence of two different killer cell populations with phenotypic similarities to NK and T cells, respectively, both being able to kill targets resistant to resting NK cells. In contrast to numerous earlier reports, we concluded that LAK cells are heterogeneous with respect to surface markers, with a major population of LAK cells apparently representing IL 2-activated cells expressing cell surface markers associated with NK cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495566

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Human lymphokine-activated killer cells develop syngeneic killing ability.

Authors:  G Gallagher; J Findlay; F A al-Azzawi
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

2.  Arsenic trioxide enhances the cytotoxic effect of thalidomide in a KG-1a human acute mylogenous leukemia cell line.

Authors:  Erian Girgis; John Mahoney; Selina Darling-Reed; Magdi Soliman
Journal:  Oncol Lett       Date:  2010-05       Impact factor: 2.967

3.  Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.

Authors:  T Y Chao; H Ohnishi; T M Chu
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

4.  Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.

Authors:  P A Lando; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

Authors:  E W Jeffes; Y B Beamer; S Jacques; R S Silberman; B Vayuvegula; S Gupta; J S Coss; R S Yamamoto; G A Granger
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

6.  Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells.

Authors:  G Gallagher; F Wilcox; F al-Azzawi
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

7.  Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.

Authors:  M Nagarkatti; P S Nagarkatti; A M Kaplan
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.

Authors:  M Suzuki; T Kikuchi; F Takatsuki; J Hamuro
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

9.  Combined activation of murine lymphocytes with staphylococcal enterotoxin and interleukin-2 results in additive cytotoxic activity.

Authors:  H Belfrage; P Bhiladvala; G Hedlund; M Dohlsten; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

Review 10.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.